Section Editors
- Paolo Bruzzi, National Cancer Research Institute
- Carlos Caldas, Cambridge Research Institute
- Ian Cree, Warwick Medical School, Coventry
- Shoukat Dedhar, British Columbia Cancer Agency
- John A Hartley, University College London
- Manami Inoue, University of Tokyo
- Mark McKeage, University of Auckland
- Christophe Nicot, Kansas University Medical Center
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
Executive Editor
- Christna Chap, BioMed Central
Editorial Board | Editorial Team | Instructions for authors | FAQ
Articles
-
BMC Cancer 2013, 13:30Childbirth in young adult cancer survivors
Recurrence-free female young adult survivors of non-gynecologic malignancies are less likely than controls to give birth after diagnosis, and the overall modest effect is influenced by pre-diagnosis childbirth and malignancy type.
-
BMC Cancer 2012, 12:553ER and PR as prognosticators in ovarian cancer
Estrogen receptors ER-alpha/-beta and progesterone receptors PR-A/-B are frequently expressed in ovarian cancer with a certain variability relating to histological subtype, grade and stage; and multivariate analysis suggests that PR-B is an independent prognostic marker for patient survival.
-
BMC Cancer 2012, 12:497hfSRT for patients with limited brain metastases
Treatment with hypofractionated stereotactic radiotherapy (hfSRT) with a cumulative EQD2 of >=35 Gy is the most effective and safe option in patients with primary or recurrent limited brain metastases despite higher rates of only mild toxicity.
-
BMC Cancer 2012, 12:496PR-104 dose for advanced solid tumors
A recommended dose of 770 mg/m2 of PR-104 given in combination with docetaxel 60-75 mg/m2, both given on day one of a 21-day treatment cycle and supported by prophylactic G-CSF, is identified in patients with advanced solid tumors.
-
BMC Cancer 2012, 12:396New model improves thyroid cancer diagnosis
A molecular computational model based on the expression of 8 genes can preoperatively distinguish benign from malignant thyroid lesions and could help identify patients with thyroid nodules who do not require radical surgery.
-
BMC Cancer 2012, 12:389Peptides predict risk of colorectal adenoma
High levels of C-peptide and insulin in normal mucosa are associated with an increased risk of developing colorectal adenomas, whilst elevated levels of IGFBP-1 (insulin-like growth factor binding protein 1) predict a reduced risk, particularly in men.
- View more articles
Hot topic
Research article
BMC Cancer 2013, 13:61
News from the web
- 01 March 2013
- Kallikrein gene variants modulate OSCC development
- 28 February 2013
- Fatigue before cancer treatment impacts fatigue afterwards
- 27 February 2013
- Local excision in elderly poor for rectal cancer survival
Scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
Latest review
Review 
Functional significance of erythropoietin in renal cell carcinoma
Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1
BMC Cancer 2013, 13:14 (10 January 2013)BMC series blog
- 01 March 2013
- Bionanotechnology in BMC Biochemistry
- 27 February 2013
- BMC Psychology officially launches!
Article Series
Cancer bioinformatics
Published: 1 May 2012
Section Editor's Profile
Prof. Carlos Caldas holds the Chair of Cancer Medicine at the University of Cambridge (UK) since 2002. He heads the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Research Institute. He is an Honorary Consultant Medical Oncologist at Addenbrooke’s Hospital, Lead of the Cambridge Experimental Cancer Medicine Centre, Co-Lead of the Cancer Theme at the NIHR Cambridge BRC and Director of the Cambridge Breast Cancer Research Unit. He is Fellow of the American College of Physicians, the Royal College of Physicians, the Royal College of Pathologists and the Society of Biology. He was elected a Fellow of the Academy of the Medical Sciences in 2004 and a Fellow of the European Academy of Cancer Sciences in 2010. He was selected as an NIHR Senior Investigator in 2012.
His current research focus is in the functional genomics of breast cancer and its biological and clinical implications. He has also a research program on the genetics of gastric cancer. His main clinical interest is in breast cancer chemotherapy and novel molecularly targeted therapies.
Prof. Caldas is the Section Editor of the Systems biology, post-genomic analysis and emerging technologies section of BMC Cancer.
Email updates
Receive periodic news and updates relating to BioMed Central straight to your inbox.
Indexed by
- CAS
- Embase
- MEDLINE
- PubMed
- Science Citation Index Expanded
- Scopus
RSS
Comments
View more comments